thereby indirectly acquire Madison National Bank, Madison Heights, Michigan.

C. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Texas Bancorp Shares, Inc., San Antonio, Texas; to acquire 100 percent of the voting shares of Camino Real Bancshares, Inc., San Antonio, Texas, and thereby indirectly acquire Camino Real Delaware, Wilmington, Delaware, and Camino Real Bank, N.A., Eagle Pass, Texas.

In connection with this application, TBSI Merging Company, Inc., San Antonio, Texas, has applied to become a bank holding company by acquiring 100 percent of the voting shares of Camino Real Bancshares, Inc., San Antonio, Texas, and thereby indirectly acquire Camino Real Delaware, Wilmington, Delaware, and Camino Real Bank, N.A., Eagle Pass, Texas.

Board of Governors of the Federal Reserve System, August 1, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–19369 Filed 8–4–95; 8:45 am]

BILLING CODE 6210–01–F

MBNA Corporation; Notice of Application to Engage de novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 21, 1995.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. MBNA Corporation, Newark, Delaware; to engage *de novo* through its subsidiary, MBNA Consumer Services, Inc., Newark, Delaware, in making, acquiring, and servicing consumer loans and credit card loans, pursuant to §§ 225.25(b)(1)(i) and (b)(1)(ii) of the Board's Regulation Y; in acquiring and servicing mortgage loans, pursuant to § 225.25(b)(1)(iii) of the Board's Regulation Y; and in offering credit insurance (life, disability, and involuntary unemployment), pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, August 1, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–19370 Filed 8–4–95; 8:45 am]

BILLING CODE 6210–01–F

Swiss Bank Corporation; Notice to Engage in Certain Nonbanking Activities

Swiss Bank Corporation, Basel, Switzerland (Applicant), has given notice pursuant to section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) (BHC Act) and § 225.23 of the Board's Regulation Y (12 CFR 225.23) to retain control of all the voting shares of certain United States subsidiaries (United States Subsidiaries) of S.G. Warburg Overseas Ltd., London, England, and the assets and liabilities of the branch of S.G. Warburg Forex Ltd., London, England, that is located in New York, New York (New York Forex), and thereby engage in the following nonbanking activities:

(1) Providing various types of investment and financial advice, pursuant to § 225.25(b)(4) of the Board's Regulation Y;

(2) Providing discount and full-service brokerage services, and activities incidental thereto, pursuant to § 225.25(b)(15) of the Board's Regulation Y;

(3) Dealing in obligations of the United States, general obligations of states and their political subdivisions, and other obligations that state member banks of the Federal Reserve System may be authorized to underwrite and deal in under 12 U.S.C. 24 and 335, pursuant to § 225.25(b)(16) of the Board's Regulation Y;

(4) Acting as agent in the private placement of all types of securities, and providing related advisory services;

(5) Underwriting and dealing in, to a limited extent, all types of debt and equity securities (other than securities issued by open-end investment companies);

(6) Trading for its own account in the option contracts as listed below:

American Stock Exchange

(i) Major Market Index options

Chicago Board Options Exchange

(ii) Standard & Poor's 100 Stock Index options

(iii) Standard & Poor's 500 Stock Index options

(vi) Long-Term Interest Rate options

(7) Trading for its own account in the futures and options on futures contracts listed as listed below:

Chicago Board of Trade

(i) Options on The Bond Buyer Municipal Bond Index futures

Chicago Mercantile Exchange

(ii) Standard & Poor's 100 Stock Price Index futures

(ii) Standard & Poor's 500 Stock Price Index futures

(iii) Options on Standard & Poor's 500 Stock Price Index futures

(vi) Eurodollar futures

Marche a Terme International de France (Paris)

(v) Cotation Assiste en Contenue (CAC) 40 Stock Index futures

(8) Trading for its own account in foreign exchange spot, forward, and futures transactions.

On June 26, 1995, Applicant received temporary authority to acquire the United States Subsidiaries and New York Forex pursuant to section 4(c)(9) of the BHC Act (12 U.S.C. 1843(c)(9)). This authority was granted in reliance upon certain commitments and conditions, including Applicant's commitment to file this notice.

The United States Subsidiaries include S.G. Warburg & Co., Inc., New York, New York (SGWC), S.G. Warburg Options Inc., Chicago, Illinois (SGWO), and S.G. Warburg OTC USA, Inc., Chicago, Illinois (SGWOTC). Applicant intends to merge SGWC with and into

SBC Capital Markets Inc., New York, New York (CMI), a subsidiary of Applicant that engages in a wide range of securities- and derivatives-related activities, including underwriting and dealing in all types of debt and equity securities on a limited basis. *See Swiss Bank Corporation*, 81 Federal Reserve Bulletin 185 (1995) (*Swiss Bank Order*). SGWO and SGWOTC will either be merged with and into CMI at the same time or liquidated promptly thereafter.

Applicant seeks approval to conduct the proposed activities throughout the United States, and plans to conduct the activities on a world-wide basis.

Closely Related to Banking Standard

Section 4(c)(8) of the BHC Act provides that a bank holding company may, with Board approval, engage in any activity ''which the Board after due notice and opportunity for hearing has determined (by order or regulation) to be so closely related to banking or managing or controlling banks as to be a proper incident thereto.''

Applicant states that the Board previously has determined by regulation or order that all of the activities conducted by the United States Subsidiaries or New York Forex, when conducted within the limitations established by the Board in its regulations and in related interpretations and orders, are closely related to banking for purposes of section 4(c)(8) of the BHC Act, and, where applicable, are consistent with section 20 of the Glass-Steagall Act (12 U.S.C. 377). *See* 12 CFR 225.25(b)(4), (b)(15), and (b)(16); *Swiss Bank Order. See also J.P. Morgan & Co. Incorporated*, 75 Federal Reserve Bulletin 192 (1989), *aff'd sub nom. Securities Industries Ass'n v. Board of Governors of the Federal Reserve System*, 900 F.2d 360 (D.C. Cir. 1990), *Order Approving Modifications to the Section 20 Orders*, 75 Federal Reserve Bulletin 751 (1989), *Canadian Imperial Bank of Commerce*, 76 Federal Reserve Bulletin 158 (1990), *Order Approving Modifications to the Section 20 Orders*, 79 Federal Reserve Bulletin 226 (1993), and *Supplement to Order Approving Modifications to Section 20 Orders*, 79 Federal Reserve Bulletin 360 (1993) (Section 20 Orders).

Applicant maintains that these activities will be conducted in conformity with the conditions and limitations established by the Board in prior cases.

Proper Incident to Banking Standard

In order to approve the proposal, the Board must determine that the proposal ''can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' 12 U.S.C. 1843(c)(8).

Applicant believes that the proposal will produce public benefits that outweigh any potential adverse effects. In particular, Applicant maintains that the proposal will enhance CMI's ability to compete with other financial institutions engaged in the investment banking business at the international level, by providing it with access to the customer base of the United States Subsidiaries and New York Forex, thereby enhancing its ability to compete in customer-oriented businesses such as underwriting and private placements in the United States. Applicant also asserts that the proposal will enable CMI to offer a broader range of products and services to its customers, and will make CMI a more effective competitor in the United States capital and securities markets. In addition, Applicant states that the proposed activities will not result in adverse effects such as an undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.

In publishing the proposal for comment, the Board does not take a position on issues raised by the proposal. Notice of the proposal is published solely in order to seek the views of interested persons on the issues presented by the notice, and does not represent a determination by the Board that the proposal meets or is likely to meet the standards of the BHC Act or other applicable laws.

Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than August 22, 1995. Any request for a hearing on this notice must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. This application may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, August 1, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–19371 Filed 8–4–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0239]

Drug Export; Neupogen® Recombinant Methionyl Granulocyte Colony Stimulating Factor (r-metHuG-CSF) With Sorbitol

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Amgen, Inc., has filed an application requesting approval for the export of the human biological product Neupogen® Recombinant Methionyl Granulocyte Colony Stimulating Factor (r-metHuG-CSF) with sorbitol in vials, pre-filled syringes, and purified bulk, to Australia, Austria, Belgium, Canada, Denmark, Finland, France, Federal Republic of Germany, Iceland, Ireland, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act